Health technology company Royal Philips has secured 510(k) market clearance from the US Food & Drug Administration (FDA) for its new Philips Capsule Surveillance solution.
The patient monitoring solution can use streaming data virtually from any medical device to generate insights and alerts that will be sent to patient caretakers for early intervention.
The latest version of Philips Capsule Surveillance is capable of working along with the hospitals’ existing mobile clinical communication, collaboration tools, electronic intensive care units (eICUs) and virtual care population health management systems.
Philips Clinical Data Services general manager Elad Benjamin said: “This FDA clearance of the latest release of clinical surveillance solution enables more integrated viewing options within EMR and HIT tools through the secure web-based user interface.
“The updated intended use provides flexible deployment configurations that Philips Capsule can offer to hospitals and health systems in the USA.
“Properly implemented clinical surveillance has the potential to significantly improve patient outcomes by helping to avoid deterioration, while also improving the care team experience via clinical decision support and minimising the burden of false and clinically unactionable alarms.”
The solution is based on the vendor-neutral Philips Capsule Medical Device Information Platform software that uses a set of smart rules based on clinical parameters and current best-practice guidelines that can be used for an individual hospital’s protocols.
Philips claims that the capsule can enable the doctors to monitor patient data, condition and alarms from devices virtually from anywhere thus reducing the chance of infection to staff in case of infectious patients.
The solution will be rolled out to limited sites across the US in the second quarter.
